Biosimilars

Latest News

Biosimilars Month in Review: June 2024
Biosimilars Month in Review: June 2024

July 5th 2024

The biosimilars month in review underscores the efficacy and safety of biosimilars in rheumatology, including recent studies supporting the growing confidence in these treatments across disease spaces.

Proposed Denosumab Biosimilar AVT03 Demonstrates Positive Topline Data
Proposed Denosumab Biosimilar AVT03 Demonstrates Positive Topline Data

July 3rd 2024

Ustekinumab-ttwe Receives FDA Approval as New Stelara Biosimilar
Ustekinumab-ttwe Receives FDA Approval as New Stelara Biosimilar

July 1st 2024

FDA Approves Eylea Biosimilar Aflibercept-mrbb for Serious Retinal Diseases
FDA Approves Eylea Biosimilar Aflibercept-mrbb for Serious Retinal Diseases

July 1st 2024

Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA
Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA

June 24th 2024

Video Interviews
Podcasts
Screenshot from podcast episode.

More News

© 2024 MJH Life Sciences

All rights reserved.